| Drug Name | Aranesp (Darbepoetin Alfa ) |
|---|---|
| Drug Class |
Hematopoietic growth factor
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Neurology
|
| Risk |
Risk of Severe Skin Reactions: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis |
| Dear Healthcare provider letter DHPC |
|